MedTrace Logo

The Long Term Outcomes After Pull-through of Long Segment Hirschsprung Disease

NCT05461924 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2022-12-01

No results posted yet for this study

Summary

Hirschsprung disease (HSCR) is characterized by the absence of ganglion cells (aganglionosis) in the distal bowel extending proximally for varying distances that results in persistent spasm in the affected bowel and functional intestinal obstruction. Patients can be classified as rectosigmoid HSCR when aganglionosis confined to the rectosigmoid and long-segment or total colonic HSCR when aganglionosis extends beyond the upper sigmoid. Aganglionosis of long-segment HSCR can extend to the descending colon, transverse colon, ascending colon, but not to the terminal ileum. To date, there is insufficient evidence to recommend a preferred or superior method for the surgical repair for long-segment HSCR. In general, a pull-through with standard of care for the intestine and mesentery, which avoids excessive resection of the colon and coloanal reconstruction, is performed for long-segment HSCR.There are reports that a significant percentage of long-segment HSCR patients continue to have difficulty with soiling and incontinence,however there were also reports long-segment HSCR patients have the same continece as rectosigmoid HSCR.The outcome of long-segment HSCR should be thoroughly evaluated. The present study was designed to evaluate the long-term outcomes of long-segment HSCR.

Conditions

  • Constipation
  • Incontinence
  • Hirschsprung Disease, Long-Segment
  • Long Term Adverse Effects

Interventions

OTHER

questionnaire survey

questionnaire survey the long term outcomes of long-segment HSCR and compared with rectosigmoid HSCR

Sponsors & Collaborators

  • Weibing Tang

    lead OTHER

Principal Investigators

  • Changgui Lu, Dr · Department of pediatric surgery of Children's hospital of Nanjing medical unverisity

Eligibility

Min Age
3 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-15
Primary Completion
2023-08-20
Completion
2023-08-20

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05461924 on ClinicalTrials.gov